Literature DB >> 29782974

Molecular therapy using siRNA: Recent trends and advances of multi target inhibition of cancer growth.

Shweta Jain1, Kamla Pathak2, Ankur Vaidya3.   

Abstract

RNA interference (RNAi) therapy, harnessed to produce a new class of drugs for treatment, has drawn attention and seen steady progress over the years. Molecular therapy using biological macromolecules small interfering RNA (siRNA) for gene silencing has received significant attention to target cancer-related genes. Basically, siRNA molecules bind to messenger RNAs (mRNA) by complementary base pairing, to induce degradation of the mRNA and/or block protein synthesis. Numerous genes and gene related proteins have been reported till date to target in siRNA based cancer therapy. Furthermore, a combination of siRNA with traditional anticancer drugs produces synergistic anticancer effect, or overcomes drug resistance, enhances targeting abilities and minimizes side-effects. Current review highlights various functional properties of genes that can be selectively knocked down by siRNAs. In addition, we have also discussed the interaction of siRNA-mediated gene-silencing with chemotherapeutic agents in nanoformulation which constitutes a valuable and safe approach for cancer treatment.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Gene therapy; Mutation; Oncogene; Silencing; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29782974     DOI: 10.1016/j.ijbiomac.2018.05.077

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  10 in total

1.  Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells.

Authors:  Golnaz Rashidi; Mahsa Rezaeepoor; Chiman Mohammadi; Ghasem Solgi; Rezvan Najafi
Journal:  Mol Biol Rep       Date:  2020-09-04       Impact factor: 2.316

2.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

3.  Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.

Authors:  Arif Khan; Masood A Khan; Ahmed N Aljarbou; Yousef H Aldebasi; Khaled S Allemailem; Mohammed A Alsahli; Shamshir Khan; Abdulmohsen M Alruwetei
Journal:  Int J Nanomedicine       Date:  2020-08-05

4.  The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer.

Authors:  Maik Friedrich; Karolin Wiedemann; Kristin Reiche; Sven-Holger Puppel; Gabriele Pfeifer; Ivonne Zipfel; Stefanie Binder; Ulrike Köhl; Gerd A Müller; Kurt Engeland; Achim Aigner; Susanne Füssel; Michael Fröhner; Claudia Peitzsch; Anna Dubrovska; Michael Rade; Sabina Christ; Stephan Schreiber; Jörg Hackermüller; Jörg Lehmann; Marieta I Toma; Michael H Muders; Ulrich Sommer; Gustavo B Baretton; Manfred Wirth; Friedemann Horn
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

Review 5.  Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.

Authors:  Ghanbar Mahmoodi Chalbatani; Hassan Dana; Elahe Gharagouzloo; Santiago Grijalvo; Ramon Eritja; Craig D Logsdon; Fereidoon Memari; Seyed Rouhollah Miri; Mahdi Rezvani Rad; Vahid Marmari
Journal:  Int J Nanomedicine       Date:  2019-05-02

6.  Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA.

Authors:  Qi Chang Zheng; Shuai Jiang; Yu Zhe Wu; Dan Shang; Yong Zhang; Shao Bo Hu; Xiang Cheng; Chen Zhang; Ping Sun; Yang Gao; Zi Fang Song; Min Li
Journal:  Front Bioeng Biotechnol       Date:  2020-06-10

7.  Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.

Authors:  Ting Pan; Qing Zhou; Kang Miao; Lei Zhang; Guorao Wu; Jun Yu; Yongjian Xu; Weining Xiong; Yong Li; Yi Wang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 8.  The Current Status of SSRP1 in Cancer: Tribulation and Road Ahead.

Authors:  Shengnan Jia; Baofeng Guo; Lihui Wang; Liping Peng; Ling Zhang
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

Review 9.  The role of microRNAs in neurodegenerative diseases: a review.

Authors:  Zhixin Lei; Taolei Sun; Shijie Li
Journal:  Cell Biol Toxicol       Date:  2022-09-20       Impact factor: 6.819

Review 10.  Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.

Authors:  Jooho Park; Yongwhan Choi; Hyeyoun Chang; Wooram Um; Ju Hee Ryu; Ick Chan Kwon
Journal:  Theranostics       Date:  2019-10-17       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.